Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Neurobiology of Disease
|
October 4, 2005
Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease
Pu-Ting Xu, Yi-Ju Li, Xue-Jun Qin, et al.
Human Vaccines & Immunotherapeutics
|
October 14, 2024
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity
Ute Klinkardt, Mirjam Schunk, John Ervin, et al.
The New England Journal of Medicine
|
February 15, 2023
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, et al.
Molecular and Cellular Neurosciences
|
September 8, 2007
A SAGE study of apolipoprotein E3/3, E3/4 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease
Pu-Ting Xu, Yi-Ju Li, Xue-Jun Qin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 31, 2022
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
Dinesh Khanna, Paul Caldron, Richard W Martin, et al.
Birth (Berkeley, Calif.)
|
August 14, 2024
Assessing patient autonomy in the context of TeamBirth, a quality improvement intervention to improve shared decision-making during labor and birth
Vanessa L Neergheen, Lynn El Chaer, Avery Plough, et al.
Human Vaccines & Immunotherapeutics
|
May 21, 2021
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
Ulrike K Buchwald, Charles P Andrews, John Ervin, et al.
The Journal of Infectious Diseases
|
January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
Kimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine
|
January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Pablo Tebas, ShuPing Yang, Jean D Boyer, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Neurobiology of Disease
|
October 4, 2005
Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease
Pu-Ting Xu, Yi-Ju Li, Xue-Jun Qin, et al.
Human Vaccines & Immunotherapeutics
|
October 14, 2024
A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity
Ute Klinkardt, Mirjam Schunk, John Ervin, et al.
The New England Journal of Medicine
|
February 15, 2023
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, et al.
Molecular and Cellular Neurosciences
|
September 8, 2007
A SAGE study of apolipoprotein E3/3, E3/4 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease
Pu-Ting Xu, Yi-Ju Li, Xue-Jun Qin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
March 31, 2022
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
Dinesh Khanna, Paul Caldron, Richard W Martin, et al.
Birth (Berkeley, Calif.)
|
August 14, 2024
Assessing patient autonomy in the context of TeamBirth, a quality improvement intervention to improve shared decision-making during labor and birth
Vanessa L Neergheen, Lynn El Chaer, Avery Plough, et al.
Human Vaccines & Immunotherapeutics
|
May 21, 2021
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
Ulrike K Buchwald, Charles P Andrews, John Ervin, et al.
The Journal of Infectious Diseases
|
January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
Kimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine
|
January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Pablo Tebas, ShuPing Yang, Jean D Boyer, et al.
Page
of 2